Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study-Reference-Cited by-同舟云学术

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

Published:2014-05-16 Issue:7 Volume:23 Page:726-734
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Grothey Axel¹,Flick E. Dawn²,Cohn Allen L.³,Bekaii-Saab Tanios S.⁴,Bendell Johanna C.⁵,Kozloff Mark⁶,Roach Nancy⁷,Mun Yong²,Fish Susan²,Hurwitz Herbert I.⁸

Affiliation:

1. Mayo Clinic; Medical Oncology; Rochester MN USA

2. Genentech Inc.; South San Francisco CA USA

3. Rocky Mountain Cancer Center; Medical Oncology; Denver CO USA

4. The Ohio State University Medical Center; Internal Medicine; Columbus OH USA

5. Sarah Cannon Research Institute; GI Cancer Research; Nashville TN USA

6. Ingalls Hospital and University of Chicago; Hematology and Oncology; Harvey IL USA

7. Fight Colorectal Cancer; Patient Advocacy; Alexandria VA USA

8. Duke University Medical Center; Division of Hematology and Oncology; Durham NC USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference16 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

2. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer;Kabbinavar;J Clin Oncol,2005

3. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200;Giantonio;J Clin Oncol,2007

4. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer;Kabbinavar;J Clin Oncol,2003

5. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial;Kabbinavar;J Clin Oncol,2005

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Personalized Oncology;Cancers;2024-08-16

2. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-06

3. An update on pharmacotherapies for colorectal cancer: 2023 and beyond;Expert Opinion on Pharmacotherapy;2024-01-02

4. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients;British Journal of Clinical Pharmacology;2023-12-29

5. Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements;Frontiers in Oncology;2023-06-20